We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Post-Marketing Clinical Study of Rebamipide in Patients With Gastric Ulcer

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: October 5, 2005
Last Update Posted: May 28, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Otsuka Pharmaceutical Co., Ltd.
To examine the efficacy of continued administration of rebamipide following bacteria eradication therapy in patients with H. pylori-positive active gastric ulcer in a placebo-controlled, double-blind study

Condition Intervention Phase
Stomach Ulcer Drug: Rebamipide Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Post-Marketing Clinical Study of Rebamipide to Investigate the Gastric Ulcer Healing Effect of Continued Dosing Following Helicobacter Pylori Eradication Therapy

Further study details as provided by Otsuka Pharmaceutical Co., Ltd.:

Primary Outcome Measures:
  • gastric ulcer healing rate

Estimated Enrollment: 300
Study Start Date: January 2004
Estimated Study Completion Date: September 2005

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients aged 20 years or older at time of consent
  2. H. pylori-positive patients meeting both of the following criteria:• Assessed as H. pylori-positive by rapid urease test and/or 13C-urea breath test at pre-study examination, • Assessed as H. pylori-antibody-positive by urine-based test after obtaining informed consent
  3. Patients endoscopically diagnosed with gastric ulcer meeting the following criteria:• Active (A1- or A2-stage by Sakita/Miwa classification), • Solitary, • Longitudinal diameter: ->5 mm
  4. Patients who have not received proton pump inhibitors (PPIs), antibacterial agents, or antiprotozoal agents within 1 week prior to endoscopy

Exclusion Criteria:

  1. Patients who have previously received H. pylori eradication therapy
  2. Patients with acute gastric ulcer
  3. Patients with linear ulcer
  4. Patients with complication of duodenal ulcer (excluding cicatrix)
  5. Patients who have undergone upper-GI tract or vagal nerve resection
  6. Patients who are unsuitable for pharmacotherapy, e.g., with perforation or pyloric stenosis
  7. Patients with gastric ulcer considered likely to induce massive hemorrhage (e.g., with obviously exposed blood vessels at lesion sites)
  8. Patients with a history of amoxicillin shock
  9. Patients with infectious mononucleosis
  10. Patients with severe renal disorders
  11. Patients with a history of hypersensitivity to penicillins, clarithromycin, lansoprazole, or rebamipide
  12. Patients who have been treated with drugs contraindicated to clarithromycin, such as terfenadine, cisapride, and pimozide
  13. Patients who are pregnant, possibly pregnant, lactating, or who desire to become pregnant during the study
  14. Patients who are otherwise judged inappropriate for inclusion in the study by the investigator or subinvestigator
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00233389

Otsuka Pharmaceutical Co., Ltd.
Tokyo, Japan
Sponsors and Collaborators
Otsuka Pharmaceutical Co., Ltd.
Study Director: Katsuhisa Saito Division of New Product Evaluation and Development
  More Information

ClinicalTrials.gov Identifier: NCT00233389     History of Changes
Other Study ID Numbers: C03700-003
First Submitted: October 4, 2005
First Posted: October 5, 2005
Last Update Posted: May 28, 2007
Last Verified: May 2007

Additional relevant MeSH terms:
Stomach Ulcer
Pathologic Processes
Peptic Ulcer
Duodenal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Stomach Diseases
Anti-Ulcer Agents
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Enzyme Inhibitors